Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01789827 · ClinicalTrials.gov registry record · Early Phase 1
Aldesleukin Imaging in Viewing Tumor Growth in Patients With Stage IV Melanoma Receiving Ipilimumab or Pembrolizumab Therapy
A Early Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 5
- Enrollment target
NCT01789827: Completed Early Phase 1 study, sponsored by Mayo Clinic.
NCT01789827 is a Early Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 5 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01789827, a Early Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
This pilot clinical trial studies aldesleukin imaging in viewing tumor growth in patients with stage IV melanoma receiving ipilimumab or pembrolizumab therapy. Diagnostic procedures, such as single-photon emission computed tomography (SPECT), uses radioactive drugs and a scanner to make detailed pictures of areas inside the body and may be a less invasive way to check for stage IV melanoma. Radioactive drugs, such as technetium Tc 99 hydrazinonicotinamide-tricine-linked interleukin-2, carry radiation directly to cancer cells and may be able to differentiate between tumor growth due to inflammation versus tumor progression in patients with stage IV melanoma receiving therapy.
Interventions
- OTHER Laboratory Biomarker Analysis
- PROCEDURE Radionuclide Imaging
- BIOLOGICAL Technetium Tc 99 Hydrazinonicotinamide-Tricine-linked Interleukin-2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2014-03 |
| Est. Completion | 2018-06-27 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01789827
The ClinicalTrials.gov registry entry for NCT01789827 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT01789827 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01789827 about?
NCT01789827 is a clinical study titled "Aldesleukin Imaging in Viewing Tumor Growth in Patients With Stage IV Melanoma Receiving Ipilimumab or Pembrolizumab Therapy". This pilot clinical trial studies aldesleukin imaging in viewing tumor growth in patients with stage IV melanoma receiving ipilimumab or pembrolizumab therapy. Diagnostic procedures, such as single-photon emission computed tomography (SPECT), uses radioactive drugs and a scanner to make detailed pic...
What is the current status of trial NCT01789827?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 5 participants. The study started on 2014-03. Estimated completion is 2018-06-27.
What interventions are being tested in trial NCT01789827?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Radionuclide Imaging (PROCEDURE), Technetium Tc 99 Hydrazinonicotinamide-Tricine-linked Interleukin-2 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01789827?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.